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Abstract
Background: Chronic inflammation is a risk factor for colorectal cancer and polymorphisms in
the inflammatory genes could modulate the levels of inflammation. We have investigated ten single
nucleotide polymorphisms (SNPs) in the following inflammation-related genes: TLR4 (Asp299Gly),
CD14 (-260 T>C), MCP1 (-2518 A>G), IL12A (+7506 A>T, +8707 A>G, +9177 T>A, +9508 G>A),
NOS2A (+524T>C), TNF (-857C>T), and PTGS1 (V444I) in 377 colorectal (CRC) cancer cases and
326 controls from Barcelona (Spain).
Results: There was no statistically significant association between the SNPs investigated and
colorectal cancer risk.
Conclusion: The lack of association may show that the inflammatory genes selected for this study
are not involved in the carcinogenic process of colorectum. Alternatively, the negative results may
derive from no particular biological effect of the analysed polymorphisms in relation to CRC.
Otherwise, the eventual biological effect is so little to go undetected, unless analysing a much larger
sample size.
Background
Epidemiological and biological data show a clear associa-
tion between chronic inflammatory conditions and sub-
sequent malignant transformation in the inflamed tissue
[1]. Inflammatory state is typically accompanied by gener-
ation of free radicals, stimulation of cytokines, chemok-
ines, and growth and angiogenic factors that favor
tumorigenesis by damaging DNA [2,3], stimulating ang-
iogenesis [4], and by inducing cell proliferation [5,6]. Fol-
lowing these considerations, some pro-inflammatory
genes have been shown to be important for the mainte-
nance and progression of cancer [7], including colorectal
cancer (CRC) [8,9].
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Toll-like and CD14 receptors are examples of pattern rec-
ognition receptors that detect antigenic molecules on the
surface of gram-positive (peptidoglycans, lipoteichoic
acid) and gram-negative (lipopolysaccharide, LPS) bacte-
ria [10]. Polymorphisms of TLR4 gene appear to be able
to alter inflammatory responses in numerous experimen-
tal and clinical models of inflammation. Asp299Gly pol-
ymorphism [dbSNP: rs4986790] within TLR4 has been
investigated by several groups and associated with an
increased response to LPS [11]. CD14 is a gene preferen-
tially expressed on monocytes/macrophages generating a
surface protein. It binds lipopolysaccharide-binding pro-
tein and recently has been shown to bind apoptotic cells
[10]. The polymorphism -260 T>C [dbSNP: rs2569190]
has been shown to increase transcriptional activity by
lowering the affinity of the GC box for Sp3, a factor
known to inhibit the activity of a number of promoters.
This enhanced transcriptional activity has been associated
with higher concentrations of soluble CD14 and
enhanced CD14 expression on the membrane of the
monocytes [12].
MCP-1 is a chemokine that is thought to be responsible
for monocyte and T-lymphocytes recruitment in acute
inflammatory conditions and may be an important medi-
ator in chronic inflammation. The G allele of -2518 A>G
MCP1 polymorphism [dbSNP: rs1024611] was found to
increase MCP-1 expression [13].
IL12A  encodes a subunit (alpha) of a cytokine that is
required for the T-cell-independent induction of inter-
feron (IFN)-gamma. IL-12 was believed to be unique in its
ability to induce the differentiation of native T cells
toward the TH1 phenotype and in its pathogenic activity,
as shown in various disease models including inflamma-
tory bowel disease (IBD) [14]. SNPs in the regulatory
sequence of IL12A are presumed to be associated with the
differential production of this cytokine [15].
Focusing on pathways involved more specifically in
chronic inflammatory bowel disorders and CRC, the nitric
oxide (NO) is a versatile molecule with actions ranging
from haemodynamic regulation to anti-proliferative
effects on vascular smooth muscle cells [16]. NO is pro-
duced by the nitric oxide synthases, endothelial NOS
(eNOS), neural NOS (nNOS), and inducible NOS
(iNOS). NOS2A is the encoding gene for the inducible
NOS. It is required for the signalling process in the innate
immunity [17] and it plays a central role on chronic
inflammatory bowel disorders [18].
Tumor necrosis factor (TNF; formerly known as TNFα)
and lymphotoxin-α ( LTA), originally characterized by
their ability to induce tumor cell apoptosis and cachexia,
are now considered as central mediators of a broad range
of biological activities (for a review see [19] and [20]).
These activities encompass beneficial effects for the host
in inflammation and in protective immune responses
against a variety of infectious pathogens [21]. In addition,
it has been demonstrated that the core members of the
TNF superfamily, including LTα, play an essential role
during the organogenesis of secondary lymphoid organs
and the maintenance of the architecture of lymphatic tis-
sues [21]. Although a large study did not show association
between polymorphisms within LTA-TNF region on chro-
mosome 6 and IBD [22], the role of LTA in the etiology of
IBD has been well ascertained in mice [23].
Several lines of evidence suggest that cyclo-oxygenases
(COX) 1 and 2 enzymes, encoded by PTGS1 and PTGS2
genes, play a significant role in colon carcinogenesis. For
example, rapid metabolism of arachidonic acid and ele-
vated levels of COX enzymes are found in several cancers,
including CRC [24]. In addition, COX enzymes have been
shown to stimulate cell proliferation, angiogenesis, and
metastasis, and to inhibit apoptosis [25]. During the
inflammatory state COX enzymes are elevated, thus the
regular use of non-steroidal anti-inflammatory drugs
(NSAIDs) could be associated with a reduced risk of CRC,
through their inhibition [26]. While COX-2 is rapidly
inducible and its expression is usually elevated at sites of
inflammation, COX-1 is considered constitutive and is
thought to be the main responsible for the cytoprotective
production of prostaglandins. However, the traditional
description of COX-1 as a purely constitutive, housekeep-
ing gene has been recently challenged by several studies,
which have found that COX-1 production can also be reg-
ulated at the transcriptional level [27].
In previous investigations, we performed a case-control
association study on several polymorphisms in genes
involved in the inflammation (namely: IL6, IL8, PPARG,
TNF, NFKB1 and PTGS2) and we found associations with
the risk of sporadic colorectal cancer [9,28]. In the present
study, in order to evaluate whether single nucleotide pol-
ymorphisms (SNPs) within more inflammatory genes
were associated with the risk to develop CRC, we investi-
gate ten SNPs in the following inflammatory genes: TLR4
(Asp299Gly),  CD14  (-260 T>C), MCP1  (-2518 A>G),
IL12A (+7506 A>T, +8707 A>G, +9177 T>A, +9508 G>A),
NOS2A (+524T>C), TNF (-857C>T), and PTGS1 (V444I)
in 377 cases and 326 controls.
Results and Discussion
Each polymorphism was in Hardy-Weinberg equilibrium
in controls. The main effects related to each polymor-
phism by case/control status are shown in Table 1. The
odd ratios (ORs) and 95% confidence interval (CI) are
shown for the codominant model. For the variant V444I
within PTGS1, we found an allele frequency too low toJournal of Negative Results in BioMedicine 2006, 5:15 http://www.jnrbm.com/content/5/1/15
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draw any conclusion, and a much larger study is necessary
to characterize better whether this SNP could play any role
in the risk of CRC. All the other polymorphisms investi-
gated showed clearly a lack of statistically significant asso-
ciation with CRC. The dominant or log-additive models
did not change substantially the results (data not shown).
No association was found when cases were classified
according to cancer site (rectal, left colon or right colon,
data not shown). The analyses for association based on
interactions of these polymorphisms with dietary varia-
bles (alcohol, tobacco, coffee, vegetables, meat and meat
products, fats, fruits, BMI, calories) did not elicit any sta-
tistical association (data not shown).
The lack of association can be due to three main reasons.
First. In spite of the importance of the inflammation for
the carcinogenic process of the colorectum, we, unfortu-
nately, selected some of the inflammatory genes that do
not have a role in this process. Second. It is also possible
that, indeed, the genes have a role for CRC, however the
selected polymorphisms do not have biological effects for
CRC. Third, it is possible that some of the SNPs have a
small effect, which undergo undetected unless studied by
analysing a much larger sample size. Although the present
study does not seem to support a role for inflammatory
polymorphisms, it should be stressed that our previous
work did show a role for a polymorphism within the pro-
Table 1: Odd ratios and 95% confidence intervals (95% CI) for colorectal cancer by genotypes under investigation.




AA 232 251 1
AG 37 31 0.75(0.45–1.27) 0.29 0.29
GG 0 0 N.A.
CD14 -260 T>C
TT 63 68 1
TC 137 151 0.98(0.65–1.50) 0.82 0.58
CC 65 62 0.87(0.53–1.43)
MCP1 -2518 A>G
AA 138 161 1
AG 97 97 0.86(0.6–1.24) 0.71 0.46
GG 16 18 0.88(0.43–1.82)
IL12A +7506 A>T
AA 97 102 1
AT 108 136 1.19(0.81–1.74) 0.49 0.99
TT 41 37 0.90(0.53–1.53)
IL12A +8707 A>G
AA 75 69 1
AG 121 149 1.30(0.86–1.96) 0.25 0.87
GG 68 59 0.94(0.58–1.53)
IL12A +9177 T>A
TT 100 108 1
TA 121 140 1.04(0.72–1.51) 0.73 0.68
AA 43 39 0.85(0.51–1.43)
IL12A +9508 G>A
GG 104 106 1
GA 124 135 1.05(0.73–1.52) 0.85 0.85
AA 40 36 0.91(0.53–1.54)
NOS2A +524T>C
TT 93 92 1
CT 127 142 1.15(0.79–1.68) 0.76 0.56
CC 45 49 1.12(0.68–1.86)
TNF -857C>T
GG 220 219 1
GA 45 58 1.32(0.85–2.04) 0.41 0.19
AA 3 4 1.55(0.34–7.09)
PTGS1 V444I
GG 265 280 1
GA 5 3 0.52(0.12–2.22) 0.36 0.36
AA 0 0 N.A.
1 P-value for the codominant model, comparing heterogeneity among three genotypes
2 P-value for the log-additive model, comparing the effect of each additional variant alleleJournal of Negative Results in BioMedicine 2006, 5:15 http://www.jnrbm.com/content/5/1/15
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moter of IL6  and the polymorphism at codon 12 of
PPARG [9]. However, IL6 and PPARG may be considered
also as part of alternative pathways not directly linked to
inflammation. IL6 is involved in the cross-talk between
neutrophiles passed into the colon lumen and colocytes
[9], whereas PPARG  is involved in the resistance to
insuline [9], thus, overall, our results seems to point
towards other mechanisms, rather than stressing the role
of inflammation for the CRC.
Conclusion
According to the results of our study, we conclude that the
SNPs analysed do not have a strong impact on the risk of
CRC.
Methods
Cases (n = 377) were patients with a new diagnosis of
CRC attending a University Hospital in Barcelona, Spain,
between January 1996 and December 1998. All cases have
had histological confirmation of their tumor diagnosis.
Participation rate among cases was 72%. Cases who did
not participate in the study were similar to those included
with respect to age, sex, tumor location, and extent.
Controls (n = 326) were randomly selected among
patients admitted to the same hospital during the same
period. To avoid selection bias, only incident cases were
selected. Participation rate among controls was 69.4%. All
subjects had the same ethnicity (Caucasian). The ethical
committee of the hospital approved the study and sub-
jects gave informed consent at recruitment. Interviews of
cases and controls were performed by trained personnel,
using a structured test to determine demographic charac-
teristics and potential risk factors for CRC. A more
detailed report on study design has been previously pub-
lished [9]. SNPs were selected based on previous publica-
tions from the literature. An extensive literature research
was carried out with the aim to study the potential role of
some inflammatory SNPs for CRC, once the information
was available for other studies.
Genotyping was carried out with the 5' nuclease assay
(TaqMan) by minor groove binder (MGB) probes fluores-
cently labelled with FAM or VIC and using the protocol
recommended by the supplier (Applied Biosystems, Fos-
ter City, CA). To ensure quality control, DNA samples
from cases and controls were randomly distributed on
PCR plates, and all genotyping was conducted by person-
nel who were blinded to case – control status. Only geno-
type calls scored concordantly by two independent
trained operators were retained. Finally, a random 8% of
the samples were re-genotyped blindly. The probes and
primers for the genotyping reactions are reported in Table
2. More details on the genotyping technique were
reported previously [9].
Each polymorphism was tested in controls to ensure that
it was in Hardy-Weinberg equilibrium. To test the hypoth-
esis of association between genetic polymorphisms and
CRC, multivariate methods based on logistic regression
analyses were used. When cases were subdivided into
groups, polytomous logistic regression was used, compar-
ing each group of cases with the whole set of controls.
Odds ratios (OR) and 95% confidence intervals (CI) were
Table 2: PCR primer and TaqMan® Probe Sequences
Gene Rs number Trivial 
name
Primer Forward Primer Reverse VIC Probe 6FAM Probe
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calculated for each group compared to the homozygotes
for the most common allele (set as having risk = 1). For
polymorphisms, homozygosity for the more frequent
allele among controls was set as the reference class. Anal-
yses were initially performed under a co-dominant model
(three genotypes separated). A log-additive model to
assess the effect of each additional rare allele and a codo-
minant model were also explored to increase the statisti-
cal power. All analyses were adjusted for age and sex and
p values were derived from likelihood ratio tests. More
details concerning the statistical analyses were published
previously [9].
The sample size of our study, for a rare allele frequency of
5%, is enough to detect ORs greater than 2 with more than
90% power assuming a log-additive model. For allele fre-
quencies of 15%, the power to detect an OR of 1.5 is 82%.
For allele frequencies of 35% as observed for some SNPs
in this study, the power to detect an OR of 1.3 is 66%.
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